Advertisement

Topics

Arrowhead to launch Phase II/III study of genetic liver disease drug

06:31 EDT 16 Apr 2019 | SmartBrief

The FDA has cleared Arrowhead Pharmaceuticals' adaptive Phase II/III trial for ARO-AAT in patients with alpha-1 antitrypsin d -More

Original Article: Arrowhead to launch Phase II/III study of genetic liver disease drug

NEXT ARTICLE

More From BioPortfolio on "Arrowhead to launch Phase II/III study of genetic liver disease drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...